Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants

References

• Lawrence RC, Felson DT, Helmick CG, et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008;58:26-35
   PubMed Web of Science ®Google Scholar
• Bennett RM, Jones J, Turk DC, et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27
   PubMed Web of Science ®Google Scholar
• Wolfe F. The epidemiology of fibromyalgia. J Musculoskelet Pain 1993;1:137-48
   Google Scholar
• Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28
   PubMed Web of Science ®Google Scholar
• Annemans L, Wessely S, Spaepen E, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum 2008;58:895-902
   PubMed Web of Science ®Google Scholar
• Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72
   PubMed Web of Science ®Google Scholar
• Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008;73:114-20
   PubMed Web of Science ®Google Scholar
• White L, Birnbaum H, Kaltenboeck A, et al. Medical care and APS-guideline-related prescription drug use in newly diagnosed and established fibromyalgia patients. J Pain 2008;9:16
   Google Scholar
• Berger A, Dukes E, Martin S, et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007;61:1498-508
   PubMed Web of Science ®Google Scholar
• Berger A, Martin S, Dukes E, et al. Patterns of pain-related pharmacotherapy in patients with fibromyalgia. Manag Care Interface 2008;20:30-8
   Google Scholar
• Berger A, Sadosky A, Dukes E, et al. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Curr Med Res Opin 2008;24:2489-99
   PubMed Web of Science ®Google Scholar
• Gore M, Sadosky A, Zlateva G, et al. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care 2010;16:S144-53
   PubMed Web of Science ®Google Scholar
• Gore M, Sadosky AB, Zlateva G, et al. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract 2009;9:363-74
   PubMed Web of Science ®Google Scholar
• Nampiaparampil DE, Shmerling RH. A review of fibromyalgia. Am J Manag Care 2004;10:794-800
   PubMed Web of Science ®Google Scholar
• White LA, Birnbaum HG, Kaltenboeck A, et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008;50:13-24
   PubMed Web of Science ®Google Scholar
• Robinson RL, Birnbaum HG, Morley MA, et al. Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently. J Rheumatol 2004;31:1621-9
   PubMed Web of Science ®Google Scholar
• Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th revision codes. J Clin Rheumatol 2006;12:124-8
   PubMed Web of Science ®Google Scholar
• Hughes G, Martinez C, Myon E, et al. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Arthritis Rheum 2006;54:177-83
   PubMed Web of Science ®Google Scholar
• Lachaine J, Beauchemin C, Landry PA. Clinical and economic characteristics of patients with fibromyalgia syndrome. Clin J Pain 2010;26:284-90
   PubMed Web of Science ®Google Scholar
• Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003;30:1318-25
   PubMed Web of Science ®Google Scholar
• Spaeth M. Epidemiology, costs, and the economic burden of fibromyalgia. Arthritis Res Ther 2009;11:117
   PubMed Web of Science ®Google Scholar
• Wassem R, Hendrix TJ. Direct and indirect costs of fibromyalgia to patients and their families. J Orthop Nurs 2003;7:26-32
   Google Scholar
• Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997;40:1560-70
   PubMed Web of Science ®Google Scholar
• Kleinman N, Harnett J, Melkonian A, et al. Burden of fibromyalgia and comparisons with osteoarthritis in the workforce. J Occup Environ Med 2009;51:1384-93
   PubMed Web of Science ®Google Scholar
• White KP, Speechley M, Harth M, et al. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario: the London Fibromyalgia Epidemiology Study. Arthritis Rheum 1999;42:76-83
   PubMed Web of Science ®Google Scholar
• Burckhardt C, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome pain in adults and children (Clinical practice guideline, no. 4). Glenview, IL: American Pain Society, 2005
   Google Scholar
• Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004;292:2388-95
   PubMed Web of Science ®Google Scholar
• Lyrica [package insert]. New York, NY: Pfizer Inc, 2007
   Google Scholar
• Cymbalta [package insert]. Indianapolis, IN: Eli Lilly & Co., 2008
   Google Scholar
• Savella [package insert]. New York, NY: Forest Pharmaceuticals, Inc., 2009
   Google Scholar
• Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 2010;11:505-21
   PubMed Web of Science ®Google Scholar
• Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain 2008;136:232-4
   PubMed Web of Science ®Google Scholar
• Zhao Y, Sun P, Sun S, et al. Comparison of dosing patterns between fibromyalgia patients with high versus low duloxetine or pregabalin compliance. Value Health 2010;13:A311
   Web of Science ®Google Scholar
• D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
   PubMed Web of Science ®Google Scholar
• Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
   Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 2008;4:605-14
   PubMedGoogle Scholar
• Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84
   PubMed Web of Science ®Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
   PubMed Web of Science ®Google Scholar
• Chappell AS, Bradley LA, Wiltse C, et al. A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2009;1:91-102
   Google Scholar
• Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004
   PubMed Web of Science ®Google Scholar
• Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409
   PubMed Web of Science ®Google Scholar
• Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14
   PubMed Web of Science ®Google Scholar
• Berger A, Dukes E, Mercadante S, et al. Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. Eur J Cancer Care (Engl) 2006;15:138-45
   PubMed Web of Science ®Google Scholar
• Gore M, Dukes E, Rowbotham D, et al. Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. Pain Pract 2006;6:265-72
   PubMedGoogle Scholar
• Verdu B, Decosterd I, Buclin T, et al. Antidepressants for the treatment of chronic pain. Drugs 2008;68:2611-32
   PubMed Web of Science ®Google Scholar